A Study of Patients With HER2-Positive Metastatic Breast Cancer

This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Signed Informed Consent document (unless the IRB has granted a waiver of consent)
Signed Authorization for the Use and Disclosure of Health Information document
HER2-positive breast cancer
Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment
Availability of cancer-specific historical data points in the patient's medical records

Exclusion criteria

There are no exclusion criteria for participation in this trial

Sponsors and collaborators

Lead sponsor

Genentech, Inc.

Industry

Registry information

Official study title

registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer

Important dates

Study start: 2003
Study completion: 2009
First posted: Mar 15, 2005
Registry last updated: May 6, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed